AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25169728 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) plus methotrexate (MTX)
Number of subjects: 556
Study 25169728 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 556
Study 25188398 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based support program (EDINA) over 4 months
Number of subjects: 105
Study 25188398 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) control condition over 4 months
Number of subjects: 105
Study 21214718 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month intervention program (cycle ergometer training twice a day for 5 days a week and a hypocaloric diet)
Number of subjects: 88
Study 21214718 — intervention group
Group type: COMPARATOR
Intervention: Control program (unchanged pharmacologic therapy without exercise and diet)
Number of subjects: 88
Study 18082776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound arm
Number of subjects: 93
Study 18082776 — intervention group
Group type: COMPARATOR
Intervention: Conventional arm
Number of subjects: 93
Study 16942453 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance exercise program
Number of subjects: 40
Study 16942453 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised walking program
Number of subjects: 40
Study 12924169 — intervention group
Group type: EXPERIMENTAL
Intervention: trandolapril (T)
Number of subjects: 39
Study 12924169 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine ER (F)
Number of subjects: 39
Study 12924169 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine (R)
Number of subjects: 39
Study 12924169 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 39
Study 11234653 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin-mineral combination (Berocca Calmag)
Number of subjects: 300
Study 11234653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 9200196 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐Bond 2/Bis‐Fil P, Unetched dentin, dry dentin
Number of subjects: 40
Study 9200196 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐Bond 2/Bis‐Fil P, Unetched dentin, moist dentin
Number of subjects: 40
Study 9200196 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐Bond 2/Bis‐Fil P, Dentin etched for 15 sec with 10% phosphoric acid, dry dentin
Number of subjects: 40
Study 9200196 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐Bond 2/Bis‐Fil P, Dentin etched for 15 sec with 10% phosphoric acid, moist dentin
Number of subjects: 40
Study 9200196 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose/Z100, Dentin etched with 10% maleic acid for 15 sec, dry dentin
Number of subjects: 40
Study 9200196 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose/Z100, Dentin etched with 10% maleic acid for 15 sec, moist dentin
Number of subjects: 40
Study 9200196 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgambond Plus/Z100, Dentin etched with 10 citric acid/3% ferric chloride, dry dentin
Number of subjects: 40
Study 9200196 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgambond Plus/Z100, Dentin etched with 10 citric acid/3% ferric chloride, moist dentin
Number of subjects: 40
Study 1312506 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (2 x 100 mg capsules taken twice in 24 hours)
Number of subjects: 214
Study 1312506 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole (500 mg vaginal tablet)
Number of subjects: 214
Study 3838625 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation with tourniquet
Number of subjects: 19
Study 3838625 — intervention group
Group type: COMPARATOR
Intervention: Operation without tourniquet
Number of subjects: 19
Study 31870634 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg daily for 26 weeks
Number of subjects: 60
Study 31870634 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 26 weeks
Number of subjects: 60
Study 30052994 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgery (shaving or disc excision)
Number of subjects: 60
Study 30052994 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical rectal surgery (segmental resection)
Number of subjects: 60
Study 30052994 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural conception
Number of subjects: 60
Study 30052994 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pregnancies recorded
Number of subjects: 60
Study 30052994 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pregnancy rate in infertile patients
Number of subjects: 60
Study 30052994 — intervention group
Group type: COMPARATOR
Intervention: Advice on natural conception vs ART
Number of subjects: 60
Study 30052994 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilities of achieving pregnancy at various months postoperatively
Number of subjects: 60
Study 26738641 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy (MET) and strengths-based case management (SBCM)
Number of subjects: 29
Study 26738641 — intervention group
Group type: COMPARATOR
Intervention: Brief feedback (BF)
Number of subjects: 29
Study 24581525 — intervention group
Group type: EXPERIMENTAL
Intervention: Wash method of specimen preparation
Number of subjects: 0
Study 24581525 — intervention group
Group type: COMPARATOR
Intervention: Swipe method of specimen preparation
Number of subjects: 0
Study 24581525 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of malignancy in biopsy specimen
Number of subjects: 0
Study 22041501 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 30
Study 22041501 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 30
Study 22041501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20066400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine alone
Number of subjects: 0
Study 20066400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine alone
Number of subjects: 0
Study 20066400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine + Nicotine
Number of subjects: 0
Study 20066400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17661853 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 1139
Study 17661853 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg BID
Number of subjects: 1139
Study 17661853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1139
Study 16051882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Number of subjects: 23
Study 16051882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 23
Study 16051882 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 23
Study 16051882 — intervention group
Group type: COMPARATOR
Intervention: Disulfiram (ALDH2 inhibition)
Number of subjects: 23
Study 12113144 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuity of care model
Number of subjects: 0
Study 10404451 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin 15 mg/kg once daily
Number of subjects: 40
Study 10404451 — intervention group
Group type: COMPARATOR
Intervention: Amikacin 7.5 mg/kg twice daily
Number of subjects: 40
Study 7481640 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 70
Study 7481640 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 70
Study 2225374 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 239
Study 2225374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 6798382 — intervention group
Group type: EXPERIMENTAL
Intervention: Briserin (Reserpine, Clopamide, Dihydroergocristine)
Number of subjects: 40
Study 6798382 — intervention group
Group type: COMPARATOR
Intervention: Reserpine/Clopamide
Number of subjects: 40
Study 31634025 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV4-HD by intramuscular injection
Number of subjects: 175
Study 31634025 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV4-HD by subcutaneous injection
Number of subjects: 175
Study 31634025 — intervention group
Group type: COMPARATOR
Intervention: IIV4-SD by subcutaneous injection
Number of subjects: 175
Study 31158245 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified directly-observed treatment (mDOT) with ledipasvir-sofosbuvir daily for 8 weeks
Number of subjects: 31
Study 31158245 — intervention group
Group type: COMPARATOR
Intervention: Unobserved treatment with ledipasvir-sofosbuvir daily for 8 weeks
Number of subjects: 31
Study 31158245 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mDOT and unobserved treatment
Number of subjects: 31
Study 27664002 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop/reduce vasoactive therapy
Number of subjects: 58
Study 27664002 — intervention group
Group type: COMPARATOR
Intervention: Continue vasoactive therapy
Number of subjects: 58
Study 26456895 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving intervention
Number of subjects: 173
Study 26456895 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 173
Study 23725521 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program (LMP) consisting of two individual and six group sessions over a nine month period.
Number of subjects: 197
Study 23725521 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program (LMP) attendance predictors.
Number of subjects: 197
Study 23725521 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative factors influencing attendance at the LMP.
Number of subjects: 197
Study 21057005 — intervention group
Group type: EXPERIMENTAL
Intervention: IMA-638
Number of subjects: 56
Study 21057005 — intervention group
Group type: EXPERIMENTAL
Intervention: IMA-026
Number of subjects: 56
Study 21057005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 19682111 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (higher-dose)
Number of subjects: 313
Study 19682111 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with depression
Number of subjects: 313
Study 19682111 — intervention group
Group type: COMPARATOR
Intervention: Subjects without depression (control)
Number of subjects: 313
Study 17442364 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinotopic motion signals
Number of subjects: 0
Study 17442364 — intervention group
Group type: COMPARATOR
Intervention: Smooth pursuit (stationary retinal image)
Number of subjects: 0
Study 15045594 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal GTN (10 mg per day)
Number of subjects: 12
Study 15045594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12385454 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA
Number of subjects: 180
Study 12385454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 9829367 — intervention group
Group type: EXPERIMENTAL
Intervention: AO-128 (2 mg three times daily)
Number of subjects: 35
Study 9829367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 7656624 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (two puffs four times a day for 7 days)
Number of subjects: 15
Study 7656624 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium (two puffs four times a day for 7 days)
Number of subjects: 15
Study 2719503 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 180
Study 2719503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 12563 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tolamolol
Number of subjects: 10
Study 12563 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg bufuralol
Number of subjects: 10
Study 12563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 10 mg tolamolol
Number of subjects: 10
Study 12563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 5 mg bufuralol
Number of subjects: 10
Study 31884303 — intervention group
Group type: EXPERIMENTAL
Intervention: hiPEM (high post-exertional malaise)
Number of subjects: 261
Study 31884303 — intervention group
Group type: COMPARATOR
Intervention: loPEM (low post-exertional malaise)
Number of subjects: 261
Study 31008935 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 120
Study 31008935 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil (group PR)
Number of subjects: 120
Study 31008935 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-midazolam-remifentanil (group PMR)
Number of subjects: 120
Study 28777828 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone Addiction Inventory (SPAI) Scale
Number of subjects: 688
Study 28777828 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression and anxiety scores
Number of subjects: 688
Study 28777828 — intervention group
Group type: COMPARATOR
Intervention: Demographic and lifestyle factors (gender, residence, work hours, faculty, GPA, smoking, alcohol drinking, religious practice)
Number of subjects: 688
Study 28777828 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality type A, younger age at first smartphone use, excessive use during a weekday, using smartphone for entertainment, not using it to call family members
Number of subjects: 688
Study 27376418 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint exercise (five × ten‐second cycle sprints)
Number of subjects: 26
Study 27376418 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive video clip
Number of subjects: 26
Study 27376418 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 26
Study 23766483 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based HIV counselling and testing
Number of subjects: 4154
Study 23766483 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care at local clinics)
Number of subjects: 4154
Study 21839414 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of anthracycline followed by docetaxel (ACD)
Number of subjects: 300
Study 21839414 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of anthracycline followed by paclitaxel (ACP)
Number of subjects: 300
Study 21839414 — intervention group
Group type: COMPARATOR
Intervention: Eight cycles of docetaxel (DTX)
Number of subjects: 300
Study 21839414 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight cycles of paclitaxel (PTX)
Number of subjects: 300
Study 19810001 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 40
Study 19810001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16722155 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation with face mask (Group B)
Number of subjects: 60
Study 16722155 — intervention group
Group type: COMPARATOR
Intervention: Conservative medical therapy (oxygen, bronchodilator, corticosteroid) (Group A)
Number of subjects: 60
Study 16722155 — intervention group
Group type: COMPARATOR
Intervention: Conservative medical therapy (Group A)
Number of subjects: 60
Study 15231444 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (n = 19)
Number of subjects: 58
Study 15231444 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (n = 18)
Number of subjects: 58
Study 15231444 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 58
Study 11071485 — intervention group
Group type: EXPERIMENTAL
Intervention: Brains with IGE
Number of subjects: 10
Study 11071485 — intervention group
Group type: COMPARATOR
Intervention: Control brains
Number of subjects: 10
Study 9282303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetropium bromide (DA3177) at a daily dose of 75 mg t.i.d. (Group D)
Number of subjects: 198
Study 9282303 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine butylbromide at a daily dose of 60 mg t.i.d. (Group B)
Number of subjects: 198
Study 9282303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetropium bromide (DA3177) (Group D)
Number of subjects: 198
Study 9282303 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine butylbromide (Group B)
Number of subjects: 198
Study 8344816 — intervention group
Group type: EXPERIMENTAL
Intervention: HyperLung (multimedia textbook)
Number of subjects: 49
Study 8344816 — intervention group
Group type: COMPARATOR
Intervention: Lecture (standard lecture)
Number of subjects: 49
Study 3028457 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg enalapril orally
Number of subjects: 6
Study 3028457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29914530 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (6 g)
Number of subjects: 39
Study 29914530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 29914530 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 39
Study 27027897 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-linear resistance training (NLRT)
Number of subjects: 30
Study 27027897 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study 24190895 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV activity
Number of subjects: 0
Study 24190895 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal variations in carriage prevalence
Number of subjects: 0
Study 23113928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task gait training
Number of subjects: 44
Study 23113928 — intervention group
Group type: COMPARATOR
Intervention: Single-task gait training
Number of subjects: 44
Study 20860598 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical termination of pregnancy (MTOP) using mifepristone and misoprostol
Number of subjects: 122
Study 20860598 — intervention group
Group type: COMPARATOR
Intervention: Surgical termination of pregnancy (STOP) by vacuum aspiration or dilatation and evacuation
Number of subjects: 122
Study 18660469 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 204
Study 16169328 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 25
Study 12534645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg twice daily for 7 days
Number of subjects: 14
Study 12534645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11011325 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacemaker programmed to VVIR or DDDR
Number of subjects: 2010
Study 8974970 — intervention group
Group type: EXPERIMENTAL
Intervention: Crataegus-Specialextract WS 1442
Number of subjects: 136
Study 8974970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 1642224 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 90
Study 1642224 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 90
Study 1642224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 1642224 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, Naproxen, Placebo
Number of subjects: 90
Study 6420340 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition via tube feeding into the first part of the jejunum
Number of subjects: 20
Study 6420340 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition via central venous catheter
Number of subjects: 20
Study 31878000 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegans
Number of subjects: 72
Study 31878000 — intervention group
Group type: COMPARATOR
Intervention: Omnivores
Number of subjects: 72
Study 29389015 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 147
Study 29389015 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 147
Study 29389015 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care (before age 20 months)
Number of subjects: 147
Study 29389015 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care (after age 20 months)
Number of subjects: 147
Study 26803764 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 129
Study 26803764 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 129
Study 27128837 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK961081 800 µg and FP 500 µg as a blend formulation
Number of subjects: 24
Study 27128837 — intervention group
Group type: COMPARATOR
Intervention: GSK961081 800 µg and FP 500 µg concurrently via separate inhalers
Number of subjects: 24
Study 27128837 — intervention group
Group type: COMPARATOR
Intervention: FP 500 µg alone
Number of subjects: 24
Study 22634355 — intervention group
Group type: EXPERIMENTAL
Intervention: New threatening information about half of the learned objects
Number of subjects: 81
Study 22634355 — intervention group
Group type: COMPARATOR
Intervention: New neutral information about half of the learned objects
Number of subjects: 81
Study 20520031 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity training
Number of subjects: 45
Study 20520031 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive training (low to mid to high fidelity)
Number of subjects: 45
Study 20520031 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity training
Number of subjects: 45
Study 19198268 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 118
Study 19198268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonotherapy (intravenous infusion of ozonized physiological solution)
Number of subjects: 118
Study 15637467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanotic CHD
Number of subjects: 56
Study 15637467 — intervention group
Group type: COMPARATOR
Intervention: Acyanotic CHD
Number of subjects: 56
Study 12682081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil (3, 10, and 30 microg/min for 5 minutes)
Number of subjects: 16
Study 12682081 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (0.75, 1.5, and 3.0 microg/min for 5 minutes)
Number of subjects: 16
Study 10708814 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg naloxone
Number of subjects: 14
Study 10708814 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 14